Touch Medical Media coverage of data presented at EADV 2021:
As always, it was an honor to speak with Prof. John E Harris (University of Massachusetts Medical School, Worcester, MA, USA) about therapies, old and new, that have been used in the treatment of vitiligo.
His presentation entitled ‘Vitiligo: from topical JAK inhibitors to anti-IL15R’ was given at the EADV 30th Congress, 29 Sep – 2 Oct 2021.
Questions
- Could you give us a brief overview of vitiligo, its prevalence and its association with other autoimmune diseases? (0:12)
- How do newer treatments compare to traditional autoimmune therapies? (0:57)
Disclosures: Prof. John E Harris has acted as a consultant and investigator for Pfizer, Genzyme/ Sanofi, Incyte, Rheos Medicines, Sun Pharmaceutical, LEO Pharma, Villaris Therapeutics, Dermavant and TeVido BioDevices; a consultant for AbbVie, Janssen, Almirall, Methuselah Health, Pandion, AnaptysBio, Avita, NIRA Biosciences, Admirx, Granular Therapeutics and Platelet BioGenesis; has Equity in TeVido Biodevices, Rheos, Villaris Therapeutics, NIRA Biosciences and is Founder of Villaris Therapeutics and NIRA Biosciences.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickleson.
Filmed in coverage of the EADV’s 30th Congress, 29 Sep – 2 Oct 2021.
This content was developed by Touch Medical Media and is not affiliated with the European Academy of Dermatology & Venereology (EADV) or the congress.
